Literature DB >> 18360293

An analysis of distal esophageal impedance in individuals with and without esophageal motility abnormalities.

Wojciech Blonski1, Amine Hila, Marcelo F Vela, Donald O Castell.   

Abstract

BACKGROUND: Combined multichannel intraluminal impedance and manometry provides simultaneous evaluation of bolus transit and pressure changes within the esophagus. The aim of this study was to analyze and to compare distal esophageal impedance values between healthy volunteers and patients with normal and abnormal esophageal manometry.
MATERIALS AND METHODS: We analyzed multichannel intraluminal impedance and manometry studies in 130 individuals (79 women, mean age 53 y, age range 17 to 85 y). There were 20 healthy volunteers and 20 patients with normal manometry. Patients with abnormal manometry were separated into nutcracker esophagus (n=20), distal esophageal spasm (n=20), ineffective esophageal motility (IEM, n=20), achalasia (n=20), and scleroderma esophagus (n=10). Manometric and MII parameters were assessed during 10 liquid and 10 viscous swallows. MII findings included esophageal impedance values and number of complete and incomplete bolus transits (CBTs). Esophageal impedance values from 2 distal impedance measuring segments (5 and 10-cm above lower esophageal sphincter) were assessed over a 2 to 3 seconds interval before the first liquid and the first viscous swallow, and 2 to 3 seconds after the tenth viscous swallow. The average values of esophageal impedance measured at 5 and 10-cm above lower esophageal sphincter (distal esophageal impedance) were calculated before liquid [distal baseline impedance (DBI)] and after 10 liquid swallows [distal liquid impedance (DLI)] and after 10 viscous swallows [distal viscous impedance (DVI)]. The correlations between DLI and DVI and number of CBT for liquid and viscous as well as distal esophageal amplitude (DEA) for liquid and viscous were also assessed using Pearson correlation coefficient.
RESULTS: Patients with achalasia or scleroderma esophagus had significantly lower DBI, DLI, and DVI than healthy volunteers, patients with normal manometry, nutcracker esophagus, or distal esophageal spasm. Patients with IEM had significantly lower DBI, DLI, and DVI than healthy volunteers or patients with nutcracker esophagus. Patients with IEM had significantly lower DLI and DVI than patients with normal manometry and significantly higher DVI than patients with achalasia. Overall, there was a significant correlation between DLI and CBTs during 10 liquid swallows (r=0.7, P<0.0001), DVI and CBTs during 10 viscous swallows (r=0.6, P<0.0001), DLI and DEA during 10 liquid swallows (r=0.5, P<0.0001), and DVI and DEA during 10 viscous swallows (r=0.5, P<0.0001).
CONCLUSIONS: Our results suggest that evaluation of distal esophageal impedance may assist in recognition and diagnosis of esophageal motility abnormalities.

Entities:  

Mesh:

Year:  2008        PMID: 18360293     DOI: 10.1097/MCG.0b013e31806daf77

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  9 in total

1.  Combined multichannel intraluminal impedance and pH monitoring assists the diagnosis of sliding hiatal hernia in children with gastroesophageal reflux disease.

Authors:  Jia-Feng Wu; Wei-Chung Hsu; Ping-Huei Tseng; Hsiu-Po Wang; Hong-Yuan Hsu; Mei-Hwei Chang; Yen-Hsuan Ni
Journal:  J Gastroenterol       Date:  2013-02-09       Impact factor: 7.527

Review 2.  Esophageal Impedance Monitoring: Clinical Pearls and Pitfalls.

Authors:  Karthik Ravi; David A Katzka
Journal:  Am J Gastroenterol       Date:  2016-06-21       Impact factor: 10.864

3.  Oesophageal baseline impedance values are decreased in patients with eosinophilic oesophagitis.

Authors:  Bram D van Rhijn; Boudewijn F Kessing; Andreas Jpm Smout; Albert J Bredenoord
Journal:  United European Gastroenterol J       Date:  2013-08       Impact factor: 4.623

4.  Diagnosis and Anti-Reflux Therapy for GERD with Respiratory Symptoms: A Study Using Multichannel Intraluminal Impedance-pH Monitoring.

Authors:  Chao Zhang; Jimin Wu; Zhiwei Hu; Chao Yan; Xiang Gao; Weitao Liang; Diangang Liu; Fei Li; Zhonggao Wang
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

5.  Reflux symptoms and oesophageal acidification in treated achalasia patients are often not reflux related.

Authors:  Fraukje A Ponds; Jacobus M Oors; André J P M Smout; Albert J Bredenoord
Journal:  Gut       Date:  2020-05-21       Impact factor: 23.059

6.  Bolus transit of upper esophageal sphincter on high-resolution impedance manometry study correlate with the laryngopharyngeal reflux symptoms.

Authors:  Jia-Feng Wu; Wei-Chung Hsu; I-Jung Tsai; Tzu-Wei Tong; Yu-Cheng Lin; Chia-Hsiang Yang; Ping-Huei Tseng
Journal:  Sci Rep       Date:  2021-10-14       Impact factor: 4.379

7.  Elevated average maximum intrabolus pressure on high-resolution manometry is associated with esophageal dysmotility and delayed esophageal emptying on timed barium esophagram.

Authors:  Katelyn E Madigan; J Shawn Smith; Joni K Evans; Steven B Clayton
Journal:  BMC Gastroenterol       Date:  2022-02-21       Impact factor: 3.067

8.  Impedance Analysis Using High-resolution Impedance Manometry Facilitates Assessment of Pharyngeal Residue in Patients With Oropharyngeal Dysphagia.

Authors:  Tae Hee Lee; Joon Seong Lee; Su Jin Hong; Ji Sung Lee; Seong Ran Jeon; Wan Jung Kim; Hyun Gun Kim; Joo Young Cho; Jin-Oh Kim; Jun-Hyung Cho; Mi-Young Kim; Soon Ha Kwon
Journal:  J Neurogastroenterol Motil       Date:  2014-07-31       Impact factor: 4.924

9.  Devices for esophageal function testing.

Authors:  Rahul Pannala; Kumar Krishnan; Rabindra R Watson; Marcelo F Vela; Barham K Abu Dayyeh; Amit Bhatt; Manoop S Bhutani; Juan Carlos Bucobo; Vinay Chandrasekhara; Andrew P Copland; Pichamol Jirapinyo; Nikhil A Kumta; Ryan J Law; John T Maple; Joshua Melson; Mansour A Parsi; Erik F Rahimi; Monica Saumoy; Amrita Sethi; Guru Trikudanathan; Arvind J Trindade; Julie Yang; David R Lichtenstein
Journal:  VideoGIE       Date:  2021-10-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.